Description

Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical firm dedicated to developing therapies for liver diseases. Its primary pipeline candidate is Aramchol, an orally administered drug currently undergoing Phase III clinical trials. This pivotal study is for the treatment of non-alcoholic steato-hepatitis (NASH) in individuals who are overweight or obese and also present with pre-diabetes or type 2 diabetes. Aramchol is also being investigated in the Phase IIa ARRIVE Study, which targets HIV-associated non-alcoholic fatty liver disease and lipodystrophy. Beyond Aramchol, the company is developing Amilo-5MER, a synthetic peptide composed of five specific amino acids: methionine, threonine, alanine, aspartic acid, and valine. Galmed has established several strategic collaborations, including: A research agreement with Gannex Pharma Co., Ltd. to develop a combination therapy for NASH, merging ASC41 (a THR-beta agonist) with Aramchol (an SCD1 inhibitor). A research and development partnership with MyBiotics Pharma Ltd. to identify specific microbiome profiles linked to how patients respond to Aramchol. A licensing agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in South Korea. Galmed Pharmaceuticals Ltd. was founded in 2000 and is based in Tel Aviv, Israel.